Navigation Links
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Date:1/31/2008

ctivity against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2).

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the validity of research results; the risk that preclinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical data suggests or as otherwise anticipated; unexpected adverse side effects or inadequate therapeutic efficacy of ADVENTRX's product candidates and other uncertainties inherent in the drug development process; the timing and success of clinical trials; difficulties or delays in developing, testing, manufacturing, and obtaining regulatory approval for ADVENTRX's product candidates; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
(Date:11/18/2008)...stCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a speci...pment Company,and Sosei Group Corporation ("Sose...onal biopharmaceutical company, today announce tha...e-clinical efficacy data for NSL-043/SD118.,This ...uropathic pain and has,successfully completed Pha...
(Date:11/18/2008)...diagnosed, elderly AML patients , , PRINCET...uticals today announced that the first patient has...dy of CPX-351 (Cytarabine:Daunorubicin) Liposome I...eloid leukemia (AML). , , The first patient...dical College of Cornell University and New York ...
(Date:11/12/2008)...D. Watson, Marilyn & James Simons and,Sherry Lansi...ov. 12 J. Craig Venter,...er Institute (JCVI), was,awarded the Double Helix ...,November 6th at a gala event in New York City., ...ith Dr. James D.,Watson for making each of their i...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 1Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 3Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 1Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 2Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 3Environmental fate of nanoparticles depends on properties of water carrying them 3161 1Environmental fate of nanoparticles depends on properties of water carrying them 3161 2Environmental fate of nanoparticles depends on properties of water carrying them 3161 3Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 1Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 2Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 3
(Date:11/21/2008)...008)The University of Texas Health Science Center ...ellence in Aging Studies (TEXAS), to promote geria...s $2 million award from the Donald W. Reynolds Fou...is will allow us to teach geriatric medicine princ...dent to practicing physicians. With the reach of L...
(Date:11/21/2008)...ain cautious about future antibiotic resistance fr...(HealthDay News) -- People with moderate to severe...be able to reduce the frequency of exacerbations t... a new report says. , The study, published in ...nal of Respiratory and Critical Care Medicine , fo...
(Date:11/21/2008)...21 NursingCenter.com, the premier ...peer reviewed content, has been,updated to improv...tered,users. Powered by Lippincott Williams &...er 900 peer-reviewed continuing education activiti...han 50 leading nursing journals.,Lippincott Willi...
(Date:11/21/2008).... 21 Barr Pharmaceutical...areholders overwhelmingly approved the proposals s...rr by Teva Pharmaceuticals Industries Ltd. (Nasdaq... the overwhelming support of the transaction by th... Chairman and CEO. "We are pleased with the progre...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...ncephalopathy (BSE) is the condition in which ther...le. It is very fatal.// The Canadian Food Inspect...he fourth cow was tested positive for this disease...ix-years old. The results of the investigation wer...
...nternational Journal of Cancer on February 17, 200...lon cancer and the level of physical activity in w...erican women has found no such link. Experts felt... the production of prostaglandins and insulin besi...
... organically have better health value. Besides bei... insecticides they increase the nutritional value ...he globe research is being done in this field. P...e harmful chemicals over food surface and cause he...
...rt attack that are commonly referred to as non-com...Indian economy, // claiming approximately $237 of ...es by World Health Organization. While India lost...the toll might reach 60 million due to health rela...
Other Medicine News:Health News:Women, Exercise and Colon Cancer 2
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: